{"sent_idx": "10", "frame_idx": "0", "ev": "At 1 year follow-up, no significant differences were observed between calcitriol and placebo groups for osteocalcin and \u03b2-CrossLaps.", "icos": [["1", "calcitriol", "placebo", "osteocalcin and \u03b2 - CrossLaps ."]], "sample": "x"}
{"sent_idx": "23", "frame_idx": "3", "ev": "At 1 year follow-up, no significant differences were observed between calcitriol and placebo groups for osteocalcin and \u03b2-CrossLaps.", "icos": [["1", "calcitriol", "placebo", "osteocalcin and \u03b2 - CrossLaps ."]], "sample": "x"}
{"sent_idx": "79", "frame_idx": "7", "ev": "At 1 year follow-up, OC and \u03b2-CrossLaps levels did not change significantly compared to diagnosis nor in the placebo not in the calcitriol-treated group.", "icos": [["1", "calcitriol", "placebo", "OC and \u03b2 - CrossLaps levels"]], "sample": "x"}
{"sent_idx": "80", "frame_idx": "8", "ev": "No significant differences were observed between calcitriol and placebo groups for OC (37.2\u00b111.8 ng/ml vs 25.8\u00b17.4 ng/ml; P = 0.39) and \u03b2-CrossLaps (0.33\u00b10.07 ng/ml vs 0.50\u00b10.12 ng/ml; P = 0.29) (table 2).", "icos": [["1", "calcitriol", "placebo", "\u03b2 - CrossLaps"]], "sample": "x"}
{"sent_idx": "80", "frame_idx": "9", "ev": "No significant differences were observed between calcitriol and placebo groups for OC (37.2\u00b111.8 ng/ml vs 25.8\u00b17.4 ng/ml; P = 0.39) and \u03b2-CrossLaps (0.33\u00b10.07 ng/ml vs 0.50\u00b10.12 ng/ml; P = 0.29) (table 2).", "icos": [["1", "calcitriol", "placebo", "OC"]], "sample": "x"}
{"sent_idx": "83", "frame_idx": "10", "ev": "No significant correlations were found at 12 months in the placebo group between OC and parameters of metabolic control, such as HbA1c, C-peptide or insulin requirement.", "icos": [["0.99837375", "placebo", "OC", "metabolic control"], ["0.994083", "placebo", "osteocalcin ( OC ),", "metabolic control"], ["0.17738803", "placebo", "regular insulin", "metabolic control"], ["0.16318688", "placebo", "placebo - controlled", "metabolic control"], ["0.12642783", "placebo", "insulin therapy", "metabolic control"]], "sample": "c"}
{"sent_idx": "83", "frame_idx": "11", "ev": "No significant correlations were found at 12 months in the placebo group between OC and parameters of metabolic control, such as HbA1c, C-peptide or insulin requirement.", "icos": [["0.9948815", "placebo", "OC", "OC"], ["0.987718", "placebo", "osteocalcin ( OC ),", "OC"], ["0.9856435", "placebo", "basal insulin", "OC"], ["0.9183405", "placebo", "placebo", "OC"], ["0.9183405", "placebo", "Placebo", "OC"]], "sample": "c"}
{"sent_idx": "83", "frame_idx": "12", "ev": "No significant correlations were found at 12 months in the placebo group between OC and parameters of metabolic control, such as HbA1c, C-peptide or insulin requirement.", "icos": [["0.9975835", "placebo", "OC", "HbA1c , C - peptide or insulin requirement ."], ["0.9918454", "placebo", "osteocalcin ( OC ),", "HbA1c , C - peptide or insulin requirement ."], ["0.021728748", "placebo", "placebo - controlled", "HbA1c , C - peptide or insulin requirement ."], ["0.021201627", "placebo", "regular insulin", "HbA1c , C - peptide or insulin requirement ."], ["0.019069878", "placebo", "insulin therapy", "HbA1c , C - peptide or insulin requirement ."]], "sample": "c"}
{"sent_idx": "118", "frame_idx": "13", "ev": "In conclusion, the results of this study indicate that supplementation with 0.25ug calcitriol per day to patients with new-onset T1D does not affect circulating markers of bone turnover.", "icos": [["0.99093354", "calcitriol", "calcitriol supplementation", "circulating markers of bone turnover ."], ["0.9241108", "calcitriol", "vitamin D supplementation", "circulating markers of bone turnover ."], ["0.9241108", "calcitriol", "Vitamin D supplementation", "circulating markers of bone turnover ."], ["0.14489587", "calcitriol", "calcitriol", "circulating markers of bone turnover ."], ["0.14489587", "calcitriol", "Calcitriol", "circulating markers of bone turnover ."]], "sample": "c"}
